¼¼°èÀÇ ¶óº£ÇÁ¶óÁ¹ ³ªÆ®·ý ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ - ¿¬·Éº°, À¯Åë ä³Îº°, ¿ëµµº°, Áö¿ªº° Àü¸Á°ú ¿¹Ãø(2024-2031³â)
Global Rabeprazole Sodium Market Size, Share & Trends Analysis Report By Age, By Distribution Channel (Drug & Retail Store Pharmacies, Hospital Pharmacies and Online Pharmacies), By Application, By Regional Outlook and Forecast, 2024 - 2031
»óǰÄÚµå : 1511396
¸®¼­Ä¡»ç : KBV Research
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 219 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,600 £Ü 4,939,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,320 £Ü 5,927,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 10¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,048 £Ü 8,298,000
PDF (Corporate User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¶óº£ÇÁ¶óÁ¹ ³ªÆ®·ý ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ µ¿¾È 3.7%ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2031³â±îÁö 8¾ï 4,530¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.

°Ô´Ù°¡ ÀǾàǰ Á¦Çü°ú ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Çõ½ÅÀº ¶óº£ÇÁ¶óÁ¹ ³ªÆ®·ýÀÇ È¿´É°ú ȯÀÚÀÇ ÄÄÇöóÀ̾𽺸¦ Å©°Ô Çâ»ó½Ã۰í À§Àå Àå¾ÖÀÇ Ä¡·áÀÇ ±âÃʷμ­ÀÇ ÁöÀ§¸¦ È®¸³Çß½À´Ï´Ù. µû¶ó¼­ ÀǾàǰ Á¦Çü°ú ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Áö¼ÓÀûÀÎ Çõ½ÅÀ¸·Î ½ÃÀå »óȲÀÌ º¯Çß½À´Ï´Ù.

±×·¯³ª ÀϺΠ¿¬±¸¿¡ µû¸£¸é À§»êÀÇ ¾ïÁ¦°¡ Àå±â°£ Áö¼ÓµÇ¸é »À °Ç°­¿¡ Áß¿äÇÑ Ä®½·ÀÇ Èí¼ö¸¦ ¹æÇØÇÒ ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù. Ä®½· Èí¼ö°¡ °¨¼ÒÇÏ¸é »ÀÀÇ ¹Ì³×¶ö ¹Ðµµ°¡ Á¤»óº¸´Ù ³·¾ÆÁö°í, ƯÈ÷ ¼Õ¸ñ, ôÃß ¹× °í°üÀýÀÇ °ñÀý À§ÇèÀÌ ³ô¾ÆÁý´Ï´Ù. µû¶ó¼­, ÀÌ·¯ÇÑ ¸ðµç ¿ì·Á°¡ ÀÌ º¸ÃæÁ¦ÀÇ µµÀÔÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

À¯Çà°ú °ü·ÃµÈ °úÁ¦¸¦ ÇØ°áÇϱâ À§ÇØ ÀÇ·á Á¦°ø ¸ðµ¨À» ÀûÀÀ½ÃÄÑ ¿ø°Ý ÀÇ·á ¼­ºñ½º¿Í ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ Çõ½ÅÀ» ÃËÁøÇß½À´Ï´Ù. ¿ø°Ý ÀÇ·á´Â ¸¸¼º À§Àå ÁúȯÀ» °ü¸®Çϰí Àá±è ¹× »çȸÀû °Å¸® È®º¸ Á¶Ä¡ ±â°£ µ¿¾È ³ëÃâ À§ÇèÀ» ÃÖ¼ÒÈ­Çϸ鼭 °ü¸® ¿¬¼Ó¼ºÀ» º¸ÀåÇϱâÀ§ÇÑ ½ÇÇà °¡´ÉÇÑ ¿É¼ÇÀ¸·Î ºÎ»óÇß½À´Ï´Ù. µû¶ó¼­ À¯ÇàÀº ½ÃÀå¿¡ Àü¹ÝÀûÀ¸·Î ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù.

¿¬·Éº° Àü¸ÁÀÔ´Ï´Ù.

³ªÀÌ¿¡ µû¶ó ½ÃÀåÀº 55¼¼ ¹Ì¸¸°ú 55¼¼ ÀÌ»óÀ¸·Î ºÐ·ùµË´Ï´Ù. 55¼¼ ¹Ì¸¸ÀÇ ºÎ¹®Àº 2023³â ½ÃÀå¿¡¼­ 67.9%ÀÇ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. ÀÌ Àα¸Åë°è¿¡´Â À§½Äµµ ¿ª·ùÁõ(GERD), ¼ÒÈ­¼º ±Ë¾ç ¹× ±âŸ »ê °ü·Ã À§Àå Àå¾ÖÀÇ ¿µÇâÀ» ¹Þ´Â ÀþÀº ¼ºÀΰú Á߳⠰³ÀÎÀÌ Æ÷ÇԵ˴ϴÙ.

À¯Åë ä³Îº° Àü¸ÁÀÔ´Ï´Ù.

À¯Åë ä³Îº°·Î º¼ ¶§ ½ÃÀåÀº º´¿ø ¾à±¹, ¾à±¹ ¹× ¼Ò¸ÅÁ¡ ¾à±¹, ¿Â¶óÀÎ °ø±ÞÀÚ·Î ³ª´µ¾îÁ® ÀÖ½À´Ï´Ù. º´¿ø ¾à±¹ ºÎ¹®Àº 2023³â ½ÃÀå¿¡¼­ 24%ÀÇ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. º´¿ø ¾à±¹Àº ÀÇ·á ÇöÀå¿¡ ÇʼöÀûÀÎ Á¸ÀçÀÌ¸ç Æ¯¼öÇÑ ÀǾàǰ ¿ä±¸¸¦ °¡Áø ÀÔ¿ø ȯÀÚ¿Í ¿Ü·¡ ȯÀÚ¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.

¿ëµµº° Àü¸ÁÀÔ´Ï´Ù.

¿ëµµ¿¡ µû¶ó ½ÃÀåÀº À§½Äµµ ¿ª·ù, ¼ÒÈ­¼º ±Ë¾ç µîÀ¸·Î ºÐ·ùµË´Ï´Ù. À§½Äµµ ¿ª·ùÁõ ºÎ¹®Àº 2023³â ½ÃÀå¿¡¼­ 58.3%ÀÇ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. ÈäÅë, ¿ª·ù, °¡½¿¾ÎÀÌ´Â À§»êÀÌ ½Äµµ·Î ¿ª·ùÇÏ´Â ¸¸¼º ¼ÒÈ­±â Áúȯ ÀÎ GERD¿Í °ü·ÃµÈ Áõ»óÀÇ ÀϺÎÀÔ´Ï´Ù.

Áö¿ªº° Àü¸ÁÀÔ´Ï´Ù.

Áö¿ªº°·Î º¸¸é ½ÃÀåÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿, ¾ÆÇÁ¸®Ä«¿¡ °ÉÃÄ ºÐ¼®µÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ºÎ¹®Àº 2023³â ½ÃÀå¿¡¼­ 25.5%ÀÇ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. ÀÌ Áö¿ª¿¡´Â µµ½ÃÈ­, ½Ä½À°ü º¯È­, ¶óÀÌÇÁ½ºÅ¸ÀÏ º¯È­·Î À§ÀåÀå¾Ö°¡ Áõ°¡Çϰí ÀÖ´Â Áß±¹, Àεµ, ÀϺ» µî ±Þ¼ÓÈ÷ ¼ºÀåÇÏ´Â °æÁ¦°¡ Æ÷ÇԵ˴ϴÙ.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦2Àå ½ÃÀå ¿ä¶÷

Á¦3Àå ½ÃÀå °³¿ä

Á¦4Àå ½ÃÀå : ¿¬·Éº°

Á¦5Àå ½ÃÀå : À¯Åë ä³Îº°

Á¦6Àå ½ÃÀå : ¿ëµµº°

Á¦7Àå ½ÃÀå : Áö¿ªº°

Á¦8Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦9Àå ¶óº£ÇÁ¶óÁ¹ ³ªÆ®·ý ½ÃÀåÀÇ ¼º°ø Çʼö Á¶°Ç

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Rabeprazole Sodium Market size is expected to reach $845.3 million by 2031, rising at a market growth of 3.7% CAGR during the forecast period.

Several factors contribute to this dominance, such as the high incidence of peptic ulcers and gastroesophageal reflux disease (GERD) in the general population. Additionally, the region boasts a well-established healthcare infrastructure, extensive insurance coverage, and high healthcare spending, facilitating access to advanced gastrointestinal treatments. The market growth of North America is further supported by the presence of prominent pharmaceutical companies and ongoing research and development initiatives. Thus, the North America region acquired 40.5% revenue share in the market 2023.

GERD is one of the most common gastrointestinal disorders. It is distinguished by the reflux of gastric acid into the esophagus, which results in symptoms such as regurgitation, chest pain, and heartburn. According to the National Library of Medicine, GERD impacts up to 20% of the adult population in Western countries.

Additionally, Innovations in pharmaceutical formulations and drug delivery systems have significantly enhanced rabeprazole sodium's efficacy and patient compliance, positioning it as a cornerstone in treating gastrointestinal disorders. Therefore, the continuous innovation in pharmaceutical formulations and drug delivery systems has transformed the market landscape.

However, several studies have indicated that prolonged suppression of stomach acid can interfere with calcium absorption, which is critical for bone health. This reduction in calcium absorption may lead to a density of bone minerals that is less than normal, which in turn elevates the risk of fractures, notably in the wrist, spine, and hip. Hence, all these concerns may impede the adoption of it.

Adapting healthcare delivery models to accommodate pandemic-related challenges fostered innovation in telehealth services and remote patient monitoring. Telemedicine emerged as a viable option for managing chronic gastrointestinal conditions, ensuring continuity of care while minimizing exposure risks during periods of lockdowns and social distancing measures. Hence, the pandemic had an overall negative impact on the market.

Age Outlook

On the basis of age, the market is classified into below 55 years and above 55 years. The below 55 years segment acquired 67.9% revenue share in the market in 2023. This demographic includes younger adults and middle-aged individuals who are increasingly affected by gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related gastrointestinal disorders.

Distribution Channel Outlook

By distribution channel, the market is divided into hospital pharmacies, drug & retail store pharmacies, and online providers. The hospital pharmacies segment garnered 24% revenue share in the market in 2023. Hospital pharmacies are integral to healthcare settings, catering to inpatients and outpatients with specialized pharmaceutical needs.

Application Outlook

Based on application, the market is characterized into gastroesophageal reflux disease, peptic ulcer, and others. The gastroesophageal reflux disease segment garnered 58.3% revenue share in the market in 2023. Chest pain, regurgitation, and heartburn are some of the symptoms associated with GERD, which is a chronic digestive ailment that is characterized by the reflux of gastric acid into the esophagus.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment acquired 25.5% revenue share in the market in 2023. This region encompasses rapidly growing economies such as China, India, and Japan, where gastrointestinal disorders are increasing due to urbanization, changing dietary habits, and lifestyle modifications.

List of Key Companies Profiled

Global Rabeprazole Sodium Market Report Segmentation

By Age

By Distribution Channel

By Application

By Geography

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Global Rabeprazole Sodium Market by Age

Chapter 5. Global Rabeprazole Sodium Market by Distribution Channel

Chapter 6. Global Rabeprazole Sodium Market by Application

Chapter 7. Global Rabeprazole Sodium Market by Region

Chapter 8. Company Profiles

Chapter 9. Winning Imperatives of Rabeprazole Sodium Market

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â